Skip to content

Head of Regulatory Affairs

Domain: Regulatory & Quality | Skill: regulatory-affairs-head | Source: ra-qm-team/regulatory-affairs-head/SKILL.md

Head of Regulatory Affairs

Regulatory strategy development, submission management, and global market access for medical device organizations.

Table of Contents

Regulatory Strategy Workflow

Develop regulatory strategy aligned with business objectives and product characteristics.

Workflow: New Product Regulatory Strategy

  1. Gather product information:
  2. Intended use and indications
  3. Device classification (risk level)
  4. Technology platform
  5. Target markets and timeline
  6. Identify applicable regulations per target market:
  7. FDA (US): 21 CFR Part 820, 510(k)/PMA/De Novo
  8. EU: MDR 2017/745, Notified Body requirements
  9. Other markets: Health Canada, PMDA, NMPA, TGA
  10. Determine optimal regulatory pathway:
  11. Compare submission types (510(k) vs De Novo vs PMA)
  12. Assess predicate device availability
  13. Evaluate clinical evidence requirements
  14. Develop regulatory timeline with milestones
  15. Estimate resource requirements and budget
  16. Identify regulatory risks and mitigation strategies
  17. Obtain stakeholder alignment and approval
  18. Validation: Strategy document approved; timeline accepted; resources allocated

Regulatory Pathway Selection Matrix

Factor 510(k) De Novo PMA
Predicate Available Yes No N/A
Risk Level Low-Moderate Low-Moderate High
Clinical Data Usually not required May be required Required
Review Time 90 days (MDUFA) 150 days 180 days
User Fee ~$22K (2024) ~$135K ~$440K
Best For Me-too devices Novel low-risk High-risk, novel

Regulatory Strategy Document Template

REGULATORY STRATEGY

Product: [Name]   Version: [X.X]   Date: [Date]

1. PRODUCT OVERVIEW
   Intended use: [One-sentence statement of intended patient population, body site, and clinical purpose]
   Device classification: [Class I / II / III]
   Technology: [Brief description, e.g., "AI-powered wound-imaging software, SaMD"]

2. TARGET MARKETS & TIMELINE
   | Market | Pathway        | Priority | Target Date |
   |--------|----------------|----------|-------------|
   | USA    | 510(k) / PMA   | 1        | Q1 20XX     |
   | EU     | Class [X] MDR  | 2        | Q2 20XX     |

3. REGULATORY PATHWAY RATIONALE
   FDA: [510(k) / De Novo / PMA] — Predicate: [K-number or "none"]
   EU:  Class [X] via [Annex IX / X / XI] — NB: [Name or TBD]
   Rationale: [2–3 sentences on key factors driving pathway choice]

4. CLINICAL EVIDENCE STRATEGY
   Requirements: [Summarize what each market needs, e.g., "510(k): bench + usability; EU Class IIb: PMCF study"]
   Approach: [Literature review / Prospective study / Combination]

5. RISKS AND MITIGATION
   | Risk                         | Prob | Impact | Mitigation                        |
   |------------------------------|------|--------|-----------------------------------|
   | Predicate delisted by FDA    | Low  | High   | Identify secondary predicate now  |
   | NB audit backlog             | Med  | Med    | Engage NB 6 months before target  |

6. RESOURCE REQUIREMENTS
   Budget: $[Amount]   Personnel: [FTEs]   External: [Consultants / CRO]

FDA Submission Workflow

Prepare and submit FDA regulatory applications.

Workflow: 510(k) Submission

  1. Confirm 510(k) pathway suitability:
  2. Predicate device identified (note K-number, e.g., K213456)
  3. Substantial equivalence (SE) argument supportable on intended use and technological characteristics
  4. No new intended use or technology concerns triggering De Novo
  5. Schedule and conduct Pre-Submission (Q-Sub) meeting if needed (see Pre-Sub Decision)
  6. Compile submission package checklist:
  7. Cover letter with device name, product code, and predicate K-number
  8. Section 1: Administrative information (applicant, contact, 510(k) type)
  9. Section 2: Device description — include photos, dimensions, materials list
  10. Section 3: Intended use and indications for use
  11. Section 4: Substantial equivalence comparison table (see example below)
  12. Section 5: Performance testing — protocols, standards cited, pass/fail results
  13. Section 6: Biocompatibility summary (ISO 10993-1 risk assessment, if patient contact)
  14. Section 7: Software documentation (IEC 62304 level, cybersecurity per FDA guidance, if applicable)
  15. Section 8: Labeling — final draft IFU, device label
  16. Section 9: Summary and conclusion
  17. Conduct internal review and quality check against FDA RTA checklist
  18. Prepare eCopy per FDA format requirements (PDF bookmarked, eCopy cover page)
  19. Submit via FDA ESG portal with user fee payment
  20. Monitor MDUFA clock and respond to AI/RTA requests within deadlines
  21. Validation: Submission accepted; MDUFA date received; tracking system updated

Substantial Equivalence Comparison Example

Characteristic Predicate (K213456) Subject Device Same? Notes
Intended use Wound measurement Wound measurement ✓ Identical
Technology 2D camera 2D + AI analysis ✗ New TC; address below
Energy type Non-energized Non-energized ✓
Patient contact No No ✓
SE conclusion New TC does not raise new safety/effectiveness questions; bench data demonstrates equivalent accuracy (±2mm vs ±3mm predicate)

Workflow: PMA Submission

  1. Confirm PMA pathway:
  2. Class III device or no suitable predicate
  3. Clinical data strategy defined
  4. Complete IDE clinical study if required:
  5. IDE approval
  6. Clinical protocol execution
  7. Study report completion
  8. Conduct Pre-Submission meeting
  9. Compile PMA submission checklist:
  10. Volume I: Administrative, device description, manufacturing
  11. Volume II: Nonclinical studies (bench, animal, biocompatibility)
  12. Volume III: Clinical studies (IDE protocol, data, statistical analysis)
  13. Volume IV: Labeling
  14. Volume V: Manufacturing information, sterilization
  15. Submit original PMA application
  16. Address FDA questions and deficiencies
  17. Prepare for FDA facility inspection
  18. Validation: PMA approved; approval letter received; post-approval requirements documented

FDA Submission Timeline

Milestone 510(k) De Novo PMA
Pre-Sub Meeting Day -90 Day -90 Day -120
Submission Day 0 Day 0 Day 0
RTA Review Day 15 Day 15 Day 45
Substantive Review Days 15–90 Days 15–150 Days 45–180
Decision Day 90 Day 150 Day 180

Common FDA Deficiencies and Prevention

Category Common Issues Prevention
Substantial Equivalence Weak predicate comparison; no performance data Build SE table with data column; cite recognized standards
Performance Testing Incomplete protocols; missing worst-case rationale Follow FDA-recognized standards; document worst-case justification
Biocompatibility Missing endpoints; no ISO 10993-1 risk assessment Complete ISO 10993-1 matrix before testing
Software Inadequate hazard analysis; no cybersecurity bill of materials IEC 62304 compliance + FDA cybersecurity guidance checklist
Labeling Inconsistent claims vs. IFU; missing symbols standard Cross-check label against IFU; cite ISO 15223-1 for symbols

See: references/fda-submission-guide.md

EU MDR Submission Workflow

Achieve CE marking under EU MDR 2017/745.

Workflow: MDR Technical Documentation

  1. Confirm device classification per MDR Annex VIII
  2. Select conformity assessment route based on class:
  3. Class I: Self-declaration
  4. Class IIa/IIb: Notified Body involvement
  5. Class III: Full NB assessment
  6. Select and engage Notified Body (for Class IIa+) — see selection criteria below
  7. Compile Technical Documentation per Annex II checklist:
  8. Annex II §1: Device description, intended purpose, UDI
  9. Annex II §2: Design and manufacturing information (drawings, BoM, process flows)
  10. Annex II §3: GSPR checklist — each requirement mapped to evidence (standard, test report, or justification)
  11. Annex II §4: Benefit-risk analysis and risk management file (ISO 14971)
  12. Annex II §5: Product verification and validation (test reports)
  13. Annex II §6: Post-market surveillance plan
  14. Annex XIV: Clinical evaluation report (CER) — literature, clinical data, equivalence justification
  15. Establish and document QMS per ISO 13485
  16. Submit application to Notified Body
  17. Address NB questions and coordinate audit
  18. Validation: CE certificate issued; Declaration of Conformity signed; EUDAMED registration complete

GSPR Checklist Row Example

GSPR Ref Requirement Standard / Guidance Evidence Document Status
Annex I §1 Safe design and manufacture ISO 14971:2019 Risk Management File v2.1 Complete
Annex I §11.1 Devices with measuring function ±accuracy EN ISO 15223-1 Performance Test Report PT-003 Complete
Annex I §17 Cybersecurity MDCG 2019-16 Cybersecurity Assessment CS-001 In progress

Clinical Evidence Requirements by Class

Class Clinical Requirement Documentation
I Clinical evaluation (CE) CE report
IIa CE with literature focus CE report + PMCF plan
IIb CE with clinical data CE report + PMCF + clinical study (some)
III CE with clinical investigation CE report + PMCF + clinical investigation

Notified Body Selection Criteria

  • Scope: Designated for your specific device category
  • Capacity: Confirmed availability within target timeline
  • Experience: Track record with your technology type
  • Geography: Proximity for on-site audits
  • Cost: Fee structure transparency
  • Communication: Responsiveness and query turnaround

See: references/eu-mdr-submission-guide.md

Global Market Access Workflow

Coordinate regulatory approvals across international markets.

Workflow: Multi-Market Submission Strategy

  1. Define target markets based on business priorities
  2. Sequence markets for efficient evidence leverage:
  3. Phase 1: FDA + EU (reference markets)
  4. Phase 2: Recognition markets (Canada, Australia)
  5. Phase 3: Major markets (Japan, China)
  6. Phase 4: Emerging markets
  7. Identify local requirements per market:
  8. Clinical data acceptability
  9. Local agent/representative needs
  10. Language and labeling requirements
  11. Develop master technical file with localization plan
  12. Establish in-country regulatory support
  13. Execute parallel or sequential submissions
  14. Track approvals and coordinate launches
  15. Validation: All target market approvals obtained; registration database updated

Market Priority Matrix

Market Size Complexity Recognition Priority
USA Large High N/A 1
EU Large High N/A 1–2
Canada Medium Medium MDSAP 2
Australia Medium Low EU accepted 2
Japan Large High Local clinical 3
China Large Very High Local testing 3
Brazil Medium High GMP inspection 3–4

Documentation Efficiency Strategy

Document Type Single Source Localization Required
Technical file core Yes Format adaptation
Risk management Yes None
Clinical data Yes Bridging assessment
QMS certificate Yes (ISO 13485) Market-specific audit
Labeling Master label Translation, local requirements
IFU Master content Translation, local symbols

See: references/global-regulatory-pathways.md

Regulatory Intelligence Workflow

Monitor and respond to regulatory changes affecting product portfolio.

Workflow: Regulatory Change Management

  1. Monitor regulatory sources:
  2. FDA Federal Register, guidance documents
  3. EU Official Journal, MDCG guidance
  4. Notified Body communications
  5. Industry associations (AdvaMed, MedTech Europe)
  6. Assess relevance to product portfolio
  7. Evaluate impact:
  8. Timeline to compliance
  9. Resource requirements
  10. Product changes needed
  11. Develop compliance action plan
  12. Communicate to affected stakeholders
  13. Implement required changes
  14. Document compliance status
  15. Validation: Compliance action plan approved; changes implemented on schedule

Regulatory Monitoring Sources

Source Type Frequency
FDA Federal Register Regulations, guidance Daily
FDA Device Database 510(k), PMA, recalls Weekly
EU Official Journal MDR/IVDR updates Weekly
MDCG Guidance EU implementation As published
ISO/IEC Standards updates Quarterly
Notified Body Audit findings, trends Per interaction

Impact Assessment Template

REGULATORY CHANGE IMPACT ASSESSMENT

Change: [Description]   Source: [Regulation/Guidance]
Effective Date: [Date]  Assessment Date: [Date]  Assessed By: [Name]

AFFECTED PRODUCTS
| Product | Impact (H/M/L) | Action Required        | Due Date |
|---------|----------------|------------------------|----------|
| [Name]  | [H/M/L]        | [Specific action]      | [Date]   |

COMPLIANCE ACTIONS
1. [Action] — Owner: [Name] — Due: [Date]
2. [Action] — Owner: [Name] — Due: [Date]

RESOURCE REQUIREMENTS: Budget $[X]  |  Personnel [X] hrs

APPROVAL: Regulatory _____________ Date _______ / Management _____________ Date _______

Decision Frameworks

Pathway Selection and Classification Reference

FDA Pathway Selection

Is predicate device available?
            │
        Yes─┴─No
         │     │
         ▼     ▼
    Is device   Is risk level
    substantially  Low-Moderate?
    equivalent?       │
         │        Yes─┴─No
     Yes─┴─No      │     │
      │     │      ▼     ▼
      ▼     ▼   De Novo  PMA
    510(k)  Consider      required
           De Novo
           or PMA

EU MDR Classification

Is the device active?
        │
    Yes─┴─No
     │     │
     ▼     ▼
Is it an   Does it contact
implant?   the body?
  │            │
Yes─┴─No   Yes─┴─No
 │    │     │     │
 ▼    ▼     ▼     ▼
III  IIb  Check   Class I
         contact  (measuring/
         type     sterile if
         and      applicable)
         duration

Pre-Submission Meeting Decision

Factor Schedule Pre-Sub Skip Pre-Sub
Novel Technology ✓
New Intended Use ✓
Complex Testing ✓
Uncertain Predicate ✓
Clinical Data Needed ✓
Well-established ✓
Clear Predicate ✓
Standard Testing ✓

Regulatory Escalation Criteria

Situation Escalation Level Action
Submission rejection VP Regulatory Root cause analysis, strategy revision
Major deficiency Director Cross-functional response team
Timeline at risk Management Resource reallocation review
Regulatory change VP Regulatory Portfolio impact assessment
Safety signal Executive Immediate containment and reporting

Tools and References

Scripts

Tool Purpose Usage
regulatory_tracker.py Track submission status and timelines python regulatory_tracker.py

Regulatory Tracker Features: - Track multiple submissions across markets - Monitor status and target dates - Identify overdue submissions - Generate status reports

Example usage: 

$ python regulatory_tracker.py --report status
Submission Status Report — 2024-11-01
┌──────────────────┬──────────┬────────────┬─────────────┬──────────┐
│ Product          │ Market   │ Type       │ Target Date │ Status   │
├──────────────────┼──────────┼────────────┼─────────────┼──────────┤
│ WoundScan Pro    │ USA      │ 510(k)     │ 2024-12-01  │ On Track │
│ WoundScan Pro    │ EU       │ MDR IIb    │ 2025-03-01  │ At Risk  │
│ CardioMonitor X1 │ Canada   │ Class II   │ 2025-01-15  │ On Track │
└──────────────────┴──────────┴────────────┴─────────────┴──────────┘
1 submission at risk: WoundScan Pro EU — NB engagement not confirmed.

References

Document Content
fda-submission-guide.md FDA pathways, requirements, review process
eu-mdr-submission-guide.md MDR classification, technical documentation, clinical evidence
global-regulatory-pathways.md Canada, Japan, China, Australia, Brazil requirements
iso-regulatory-requirements.md ISO 13485, 14971, 10993, IEC 62304, 62366 requirements

Key Performance Indicators

KPI Target Calculation
First-time approval rate >85% (Approved without major deficiency / Total submitted) × 100
On-time submission >90% (Submitted by target date / Total submissions) × 100
Review cycle compliance >95% (Responses within deadline / Total requests) × 100
Regulatory hold time <20% (Days on hold / Total review days) × 100
Skill Integration Point
mdr-745-specialist Detailed EU MDR technical requirements
fda-consultant-specialist FDA submission deep expertise
quality-manager-qms-iso13485 QMS for regulatory compliance
risk-management-specialist ISO 14971 risk management